https://www.selleckchem.com/pr....oducts/CP-690550.htm
, Development, and Evaluation certainty of evidence ranged from very low to moderate. We recommend the use of prophylactic anticoagulation against intermediate-to-therapeutic anticoagulation among unselected hospitalized COVID-19 patients considering insignificant survival benefits but higher risk of bleeding in the escalated thromboprophylaxis strategy. For critically ill COVID-19 patients, the benefits of intermediate-to-therapeutic anticoagulation in reducing thrombotic events should be weighed cautiously because of its association
Like
Comment
Share
